Mersana Therapeutics Inc. announced an amendment to its bylaws to implement a 1-for-25 reverse stock split of its common stock, effective July 25, 2025. This move aims to comply with the Nasdaq Global Select Market's minimum bid price requirement. The stock will trade under the symbol "MRSN" with a new CUSIP number, 59045L205, starting July 28, 2025. Fractional shares will not be issued, with cash payments provided instead.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.